Families count on you. You can count on us.
60,000+ babies safely fed Evivo. 4,500,000+ servings given.
Evivo with MCT Oil
Inquire about this productEvivo infant probiotic is intended for babies of all sizes, fed any amount of colostrum or human milk, including donor milk. Feed Evivo right after birth, once a day, orally or via feeding tube.
This formulation is specifically created for use in health facilities to eliminate powder handling as recommended by the CDC and FDA.
- Made with medium chain triglyceride (MCT) oil
- Single-serve, ready-to-use liquid
Safe & well tolerated by term and preterm infants.
Clean Label Project Certified and “First 1,000 Day Promise” certification.
Administering human-milk fed NICU infants Evivo can modulate inflammation by reducing potential gut pathogens and concurrently increasing beneficial bifidobacteria in the preterm gut.
Clinically shown to:
- Fully utilize Human Milk Oligosaccharides (HMOs) found in breast milk, helping infants maximize nutrition
- Colonize the gut to establish a persistent protective presence of B. infantis EVC001
- Protect barrier function (mucin barrier)
- Suppress growth of potentially pathogenic bacteria
- Reduce antibiotic resistance genes (ARGs) abundance in the microbiome
- Significantly reduce intestinal inflammation
Safe to feed and well-tolerated by Very Low Birth Weight infants (VLBWs) and other high-risk infant groups.
Administer Evivo to babies fed any amount of human milk to help establish a protective gut microbiome and support healthy immune function.
Early, proactive attention to the gut microbiome is especially key for:
- Babies born by C-section
- Infants born of mothers treated with antibiotics prior or during delivery
- Infants treated with antibiotics
- Infants with a family history of food allergy, asthma, eczema, or autoimmune disease
Clinically shown to:
- Promote the growth of beneficial B. infantis EVC001 to establish a healthy gut microbiome
- Guide immune system from an immunoreactive state to an immunoregulated state
- Protects from potentially harmful bacteria linked to colic, diaper rash, eczema, food allergies, and type 1 diabetes
- Convert breast milk HMOs into metabolites that help guide healthy immune function
How does Evivo work with breast milk to protect babies from within?
See our documented mechanism of action.
Capture
B. infantis EVC001 uniquely captures Human Milk Oligosaccharides (HMOs) found in breast milk, helping infants maximize nutrition from breast milk.
Consume
B. infantis EVC001 then consumes HMOs to colonize, or to replicate, establish, and persist, in the gut and help protect baby from potential pathogens, some of which may be linked to inflammation.
Convert
Finally, B. infantis EVC001 converts HMOs into metabolites, key signaling molecules that help guide healthy immune system function. An overactive immune system has been associated with the development of allergies and other autoimmune conditions later in life.
We know how Evivo works, have a documented mechanism of action, and can support our claims with scientific evidence – that sets us apart from others.
Effects of probiotic and symbiotic supplementation on ponderal and linear growth in severely malnourished young infants in a randomized clinical trial
A single blind randomized clinical trial during the rehabilitation of <6-month-old infants with severe acute malnutrition in Bangladesh. Four weeks after the supplementation period, signs of improved ponderal growth (e.g. rate of weight gain and WAZ scores were significantly higher in infants who had been supplemented with the probiotic (B. infantis EVC001) for 28 days.
Preterm infant fecal microbiota and metabolite profiles are modulated in a probiotic specific manner
In this single-center observational cohort study demonstrates that supplementing an HMO-catabolizing Bifidobacterium probiotic (B. infantis EVC001) results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a non-catabolizing Lactobacillus probiotic in human milk-fed preterm infants.
Bifidobacterium infantis EVC001 administration is associated with a significant reduction in incidence of Necrotizing Enterocolitis in very low birth weight infants
A retrospective observational analysis of two cohorts of very low birth weight (VLBW) infants (+/-) B. infantis EVC001) demonstrated that B. infantis EVC001 was associated with a significant reduction in necrotizing enterocolitis (NEC) and NEC-related mortality.
B. infantis EVC001 is well-tolerated and improves Human Milk Oligosaccharide (HMO) utilization in preterm infants in the neonatal intensive care unit
A prospective, open-label study was used to evaluate the tolerability and HMO-utilization capacity of B. infantis EVC001 and its effects on the fecal microbiota in thirty preterm infants <1,500 g and/or <33 weeks gestation at birth. B. infantis EVC001 was shown to be safe, well-tolerated, and efficient in colonizing the preterm infant gut and able to increase the abundance of bifidobacteria capable of metabolizing HMOs, resulting in significantly improved utilization of human milk.
Bifidobacteria-mediated immune system imprinting early in life
This study identified a correlation between low Bifidobacteria abundance in infant gut microbiome and increased systemic and enteric inflammation. In vitro studies showed fecal metabolites from infants who were colonized with B. infantis EVC001 polarize naïve CD4 T cells away from Th17 (autoimmune) and Th2 (allergic) phenotype towards Th1 (tolerogenic).
Impact of probiotic B. infantis EVC001 feeding in premature infants on the gut microbiome, nosocomially acquired antibiotic resistance, and enteric inflammation
An observational study in premature infants showing changes in microbiome composition, as well as significantly reduced antibiotic resistant gene abundance, enteric inflammation, diaper rash, and antibiotic use in infants fed B. infantis EVC001 compared to infants that were not fed the probiotic.
Symptomatic relief from at-home use of activated Bifidobacterium infantis EVC001 probiotic in infants: results from a consumer survey on the effects on diaper rash, colic symptoms, and sleep
A post-purchase consumer survey reported improvements in diaper rash, gassiness/fussiness, and sleep behavior in infants fed B. infantis EVC001.
Comparative Genome Analysis of Bifidobacterium longum subsp. infantis strains reveals variation in human milk oligosaccharide utilization genes among commercial probiotics
Study finds important differences in the genetic makeup of commercial B. infantis strains, specifically on genes related to the metabolization of human milk oligosaccharides. Compared to H5 positive which are fully equipped, H5 negative strains are missing genes related to HMO uptake and attain lower density in vitro and in vivo in a proof-of-concept study.
Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds 40d old control infants exhibit chronic enteric inflammation, which is significantly different from infants colonized with B. infantis EVC001.
N-glycans from human milk glycoproteins are selectively released by an infant gut symbiont in vivo
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days. Study finds a significantly higher abundance of N-glycans released from milk glycoproteins in the infants fed EVC001 group compared with exclusively breastfed controls.
Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria
Analysis of infants’ fecal samples from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds an 80% reduction in the carriage of antibiotic resistance genes (ARGs) in infants colonized with B. infantis.
Colonization of breastfed infants byBifidobacterium longum subsp. infantis EVC001 reduces virulence gene abundance
Analysis of infants’ fecal samples from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days finds a significant reduction of gut pathogens (identified by virulence factors) in infants colonized with B. infantis compared to those not fed the probiotic.
Reduced colonic mucin degradation in breastfed infants colonized by Bifidobacterium longum subsp. infantis EVC001
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days of life find a significant reduction in mucous erosion in infants colonized with B. infantis EVC001 compared to those not fed the probiotic.
Persistence of supplemented Bifidobacterium longum subsp. infantis EVC001 in breastfed infants
Analysis of fecal samples of a subset of infants from a randomized open-label trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis for the first 21 days. A study finds a significantly higher abundance of B. infantis (by qPCR) and relative abundance of Bifidobacterium (by 16S rRNA sequencing) in infants fed with B. infantis EVC001 relative to the microbiome exclusively breasted control infants.
Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase 1 clinical trial
Open-label clinical trial to determine the effects of supplementing the probiotic Bifidobacterium longum subsp. infantis EVC001 for the first 21 days of life in healthy term breastfed infants compared with matched-control term infants receiving standard care. B. infantis EVC001 was found to be safely consumed and well-tolerated. Stools were fewer and better formed in infants in infants fed EVC001 group compared with exclusively breastfed controls. Adverse events were those expected in healthy infants and not different between groups.
Keep your patients on the path to good health with Evivo at home
It’s exciting when baby goes home. Fortunately, parents can continue helping baby maintain a healthy gut after discharge.
When parents continue feeding Evivo as recommended, they:
- Promote continued growth of beneficial B. infantis EVC001
- Help baby maintain a healthy gut microbiome
- Protect from potentially harmful bacteria linked to colic, digestive discomfort, diaper rash, eczema, allergies, and type 1 diabetes
- Support immune function during a key time for immune system education
Surpassing safety and quality standards
Delivering high-quality, safe products for babies is our top priority. That’s why we’re committed to products that go above and beyond stringent FDA regulatory requirements.
Clinically shown to be safe and well tolerated
In clinical trials and in real-world use, Evivo is shown to be safe. It’s been given to more than 60,000 babies, with over 4.5 million feedings to date, and more babies are being fed every day.
Highest standards for purity and quality
Evivo received the “Clean Label Project” and “First 1,000 Day Promise” certifications. An award given to products that emphasize purity and surpass FDA regulations. We are proud to be the first product that promotes health for infants both in hospitals and at home to receive these designations.
Manufactured in a dedicated ISO-8 clean room
Evivo is manufactured in the USA using high-quality ingredients in an FDA-compliant, inspected, and regulated setting and further protected by cold-chain distribution.
A CFU guarantee in every serving
We’re proud to say that we guarantee consistency in every vial of Evivo, with 8 Billion CFU per serving. When you feed Evivo to your patients, feel confident what you are administering
Food for Special Dietary Use, FDA designation
Evivo is designated as a Food for Special Dietary Use (FDA CFR21 part 105), not a supplement, and is generally regarded as safe (GRAS) for its intended use in preterm and term infants having a source of HMOs in their diet.
Frequently Asked Questions
Infant health is your priority, so you likely have questions. You can contact us directly at (844) 436-8486, email customerservice@evivo.com, or search our FAQs for an answer.
Evivo is for all human milk or mix-fed (breastmilk + formula) babies, and in particular: Newborns exposed to antibiotics or of mothers treated with perinatal antibiotics E.g., Born by C-section, infants of GBS strep-positive mothers and cases of chorioamnionitis. Also, infants with a family history of food allergy, asthma, eczema, or autoimmune disease.
Evivo contains B. infantis, a natural infant-specific strain that has evolved with humans for millions of years to work with breast milk. Because of these characteristics Evivo provides superior colonization. When combined with breast milk, Evivo works by favorably changing gut biochemistry to reduce potentially harmful bacteria and intestinal inflammation, both of which have been linked to increased risk of short- and long-term health problems. The combination of Evivo and breast milk creates a protective infant gut environment, creating a foundation for good health.
In addition to routine lab testing and formulation review, Clean Label Project performs random sampling and testing to ensure ongoing compliance with standards.
Connect with us
Call us at (844) 463-8486 for customer service, support, and to learn more about our products.